Lexaria Bioscience reaches full enrollment in oral semaglutide study
LEXX•Lexaria Bioscience reported full enrollment in its five-week human pilot study of two oral DehydraTECH-semaglutide formulations, with dosing on schedule. The study compares the formulations with Novo's Wegovy tablets and is expected to finish dosing in mid-November.
1. Study enrollment complete
Lexaria Bioscience reported full enrollment in its GLP-1-H26-7 human pilot study on October 21, 2026. The final group began dosing in early October, and dosing is expected to finish in mid-November.
2. Study design and results
The five-week trial compares two oral DehydraTECH-semaglutide formulations with Novo's Wegovy tablets, assessing safety, tolerability and drug absorption. Results will follow completion of dosing and laboratory analyses; Lexaria plans a progress update once dosing ends. Existing corporate resources fully fund the study.
